论文信息 - Heterologous vaccine regimens against COVID-19 - 字舞流文

Heterologous vaccine regimens against COVID-19

D. Prieto-Alhambra | T. Duarte-Salles

[1] A. Borobia,et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial , 2021, The Lancet.

[2] S. Schneitler,et al. Immunogenicity and reactogenicity of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens , 2021, medRxiv.

[3] M. Suchard,et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study , 2021, BMJ.

[4] M. Snape,et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data , 2021, The Lancet.

[5] Hannah Ritchie,et al. A global database of COVID-19 vaccinations , 2021, Nature Human Behaviour.

[6] P. McKay,et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice , 2021, Nature Communications.

[7] Medicines And Healthcare Products Regulatory Agency , 2020, Definitions.